acamprosate vs buprenorphine
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of acamprosate and buprenorphine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Campral
Subutex, Sublocade
Acamprosate is a medicine that can help you stay away from alcohol if you are alcohol-dependent and have already stopped drinking. It should be used with counseling and support.
Buprenorphine sublingual tablets help treat opioid dependence. It should be part of a full treatment plan with counseling and support.
Acamprosate helps people who are alcohol-dependent to not drink alcohol. You must have already stopped drinking before you start taking acamprosate. This medicine works best when it is part of a complete treatment plan that includes counseling and support.
This medicine treats opioid dependence. Opioid dependence means you feel like you need to take opioids. This medicine can help you manage withdrawal symptoms and reduce cravings.
Acamprosate is similar to a natural substance in your brain. It is thought to work by helping to restore the normal balance of brain activity that is changed by long-term alcohol use. This can reduce your craving for alcohol.
Buprenorphine is a partial opioid agonist. This means it binds to the same receptors in the brain as opioids, but it does not activate them as strongly. This helps to reduce cravings and withdrawal symptoms without causing the same high as other opioids.
- • Accidental injury
- • Weakness
- • Pain
- • Loss of appetite
- • Diarrhea
- • Headache
- • Nausea
- • Vomiting
- • Sweating
- • Constipation
- Hypotension 14
- Asthenia 13
- Condition Aggravated 13
- Acute Kidney Injury 12
- Coma 12
- Death 13,278
- Drug Dependence 12,452
- Overdose 10,911
- Toxicity To Various Agents 10,722
- Pain 8,157
Acamprosate may increase the risk of suicidal thoughts or actions. Your doctor should watch you for depression or suicidal thoughts. Tell your doctor right away if you have any new or worsening symptoms of depression or suicidal thoughts.
Buprenorphine can be abused, like other opioids. Taking buprenorphine with benzodiazepines or other depressants can cause serious breathing problems, coma, or death. Keep this medicine out of the reach of children, as it can cause severe breathing problems and death. Using opioids for a long time during pregnancy can cause withdrawal symptoms in the newborn.
Acamprosate may harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if acamprosate passes into breast milk. Talk to your doctor if you are breastfeeding.
If you are pregnant or plan to become pregnant, talk to your doctor. Using this medicine during pregnancy can cause withdrawal symptoms in your baby after birth. Buprenorphine can pass into breast milk.
Also Compare, Nearby Drugs
Compare buprenorphine with
How to Read This acamprosate vs buprenorphine Comparison
acamprosate is classified in the GABA Analog (Alcohol Dependence) drug class, while buprenorphine sits within the Partial Opioid Agonist class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, acamprosate has 64 submissions while buprenorphine has 55,520. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for acamprosate or buprenorphine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.